Jack A. Khattar - 13 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: President, CEO, Director
Issuer ticker: SUPN
Reported as of: 13 Mar 2026
Net transaction value: -$1,763,124
SEC form: 4
Accepted by SEC: 16 Mar 2026, 16:08:19 UTC
Prior SEC filing: 10 Mar 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Jack A. Khattar filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 16 Mar 2026.

Key facts

This page summarizes Jack A. Khattar's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Mar 2026, 16:08.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: -$1,763,124.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001539937 Primary reporting owner

Khattar Jack A.

Relationship: President, CEO, Director
Address: C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Other

Transaction value
Shares: +12,500
Change %: +1%
Price
Shares after: 1,241,144
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1

SUPN transaction

Common Stock

Other

Transaction value
Shares: -12,500
Change %: -1.2%
Price
Shares after: 993,100
Date: 13 Mar 2026
Ownership: By the KBT Trust
Footnotes: F1

SUPN transaction

Common Stock

Sale

Transaction value: $1,209,072
Shares: -24,138
Change %: -2.4%
Price: $50.09
Shares after: 968,962
Date: 13 Mar 2026
Ownership: By the KBT Trust
Footnotes: F2, F3

SUPN transaction

Common Stock

Sale

Transaction value: $547,842
Shares: -10,742
Change %: -1.1%
Price: $51.00
Shares after: 958,220
Date: 13 Mar 2026
Ownership: By the KBT Trust
Footnotes: F2, F4

SUPN transaction

Common Stock

Sale

Transaction value: $6,210
Shares: -120
Change %: -0.01%
Price: $51.75
Shares after: 958,100
Date: 13 Mar 2026
Ownership: By the KBT Trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly.

Footnote F2

Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.